BBIO Q3 2021 Earnings — BridgeBio Pharma, Inc. Revenue & Financial Results | Market Cap Arena

BBIOBridgeBio Pharma, Inc.

$14B

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M-71.2% YoY

Gross Profit

$890,00038.0% margin

Operating Income

-$149M-6377.9% margin

Net Income

-$156M-6652.5% margin

EPS (Diluted)

$-1.06

QoQ Revenue Growth

-95.7%

Cash Flow

Operating Cash Flow

-$122M

Free Cash Flow

-$163M

Stock-Based Comp.

$16M

Balance Sheet

Total Assets

$782M

Total Liabilities

$1.5B

Stockholders' Equity

-$743M

Cash & Equivalents

$180M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$8M	-71.2%
Gross Profit	$890,000	$8M	-89.0%
Operating Income	-$149M	-$120M	-24.6%
Net Income	-$156M	-$116M	-34.6%

Revenue Segments

License

$2M68%

Product

$759,00032%